CLIMARA PRO
LOE Approachingestradiol; levonorgestrel
NDATRANSDERMALSYSTEM
Approved
Dec 2005
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
4/8 — Partial
CLIMARA PRO (estradiol; levonorgestrel) is characteristics. Approved for a woman with a uterus for: treatment of moderate to severe vasomotor symptoms due to menopause () prevention of postmenopausal osteoporosis () limitations of use:, first consider the use of non-estrogen medications, osteoporosis and 1 more indications. First approved in 2005.
Drug data last refreshed 4d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CLIMARA PRO is a transdermal hormone replacement therapy combining estradiol and levonorgestrel for moderate to severe vasomotor symptoms and osteoporosis prevention in postmenopausal women. Estradiol acts as the principal intracellular estrogen binding to nuclear receptors, while levonorgestrel counteracts estrogen-induced endometrial proliferation through gonadotropin inhibition. The combination leverages estrogen receptor agonism with progestin protection in a patch delivery system.
$0.004BPart D
LOE ApproachingApproaching loss of exclusivity signals potential team rationalization; modest Part D spending ($4M, 8,059 claims in 2023) indicates niche positioning with limited growth runway.
Mechanism of Action
characteristics. Although circulating estrogens exist in a dynamic equilibrium of metabolic interconversions, estradiol is the principal intracellular human estrogen and is substantially more potent than its metabolites, estrone and estriol, at the receptor level. The primary source of estrogen in…
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.